Characterizing the Patient Experience of CS/HIPEC Through In-Depth Interviews with Patients: Identification of Key Concepts in the Development of a Patient-Centered Program

Francescutti, Valerie; Maciver, Allison H.; Stewart, Erika; Clark, Nikia; Marrara, Bianca; Saad‐Harfouche, Frances G.; Rodriguez, Elisa M.

doi:10.1245/s10434-018-07120-x

Cited by 7 publications

(3 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While the optimal form of preoperative counselling for CRS±HIPEC has not been determined, a recent study showed that patients preparing for CRS±HIPEC overwhelmingly requested audiovisual or mixed-type educational information, related to preoperative decision-making and the recovery process, as opposed to just written materials. The study also found that including caregivers as key members of the recovery process within the preoperative counselling programme is essential [13].…”

Section: Preadmission Information Education and Counsellingmentioning

confidence: 85%

Guidelines for Perioperative Care in Cytoreductive Surgery (CRS) with or without hyperthermic IntraPEritoneal chemotherapy (HIPEC): Enhanced recovery after surgery (ERAS®) Society Recommendations — Part I: Preoperative and intraoperative management

Hübner

Kusamura

Villeneuve

et al. 2020

European Journal of Surgical Oncology

109

View full text Add to dashboard Cite

show abstract

Section: Preadmission Information Education and Counsellingmentioning

confidence: 85%

Guidelines for Perioperative Care in Cytoreductive Surgery (CRS) with or without hyperthermic IntraPEritoneal chemotherapy (HIPEC): Enhanced recovery after surgery (ERAS®) Society Recommendations — Part I: Preoperative and intraoperative management

Hübner

Kusamura

Villeneuve

et al. 2020

European Journal of Surgical Oncology

109

View full text Add to dashboard Cite

show abstract

“…These included chronic pain, diet restrictions, ongoing gastrointestinal problems, and sleep difficulties. 40 In other cases, patients described crying spells, depression, and stoma-related problems (e.g., social issues, negative effect on intimate relationships, and constant reminder of disease), 41 as well as uncertainty about the future or death. 42 These symptoms and their impact on QoL can be missed when using questionnaires that are not disease specific.…”

Section: Discussionmentioning

confidence: 99%

Systematic Review of Factors Affecting Quality of Life After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy

et al. 2020

View full text Add to dashboard Cite

Background. Previous studies have shown that, overall, quality of life (QoL) decreases within the first 3-6 months after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS ? HIPEC), returning to baseline levels by 6-12 months. This systematic review aims to evaluate the factors affecting QoL after CRS ? HIPEC within 12 months of surgery. Methods. Electronic databases were investigated searching for articles reporting QoL with validated questionnaires up to September 2019. Risk of bias was assessed with the methodological index for non-randomized studies tool. The primary outcomes were short-term (\ 6 months after surgery) and medium-term (6-12 months after surgery) determinants of QoL after CRS ? HIPEC. Secondary outcomes were QoL and reported symptoms over time. Results. We included 14 studies that used 12 different questionnaires. The reported data were collected prospectively or retrospectively for 1556 patients (dropout \ 50% in four studies). Overall, studies showed diminished QoL within 3 months after surgery and a recovery to baseline or greater by 12 months. QoL was negatively influenced by higher age, female sex, prolonged operation time, extensive disease, residual disease, adjuvant chemotherapy, complications, stoma placement, and recurrent disease. QoL results were comparable between studies, with dropout rates above and below 50%. Conclusions. QoL returns to baseline levels within 12 months after CRS ? HIPEC provided the disease does not recur, and this recovery process is influenced by several factors.

show abstract

“…A close partnership between doctors, patients and their families with transparent and honest informa tion on expected benefits, potential risks and treatment options is therefore of utmost importance to define the optimal treatment for the individual patient by shared decision making. Frequently, there is already a profound misunderstanding between patients and care providers concerning the intent of treatment and prognosis [356][357][358] . Although patients with potentially curable disease are more likely to accept treatment related adverse effects with effects on QoL and functioning, priorities and expectations might be very different in the palliative setting.…”

Section: Quality Of Lifementioning

confidence: 99%

Primary and metastatic peritoneal surface malignancies

2021

Nat Rev Dis Primers

View full text Add to dashboard Cite

Peritoneal surface malignancies comprise a heterogeneous group of primary tumours, including peritoneal mesothelioma, and peritoneal metastases of other tumours, including ovarian, gastric, colorectal, appendicular or pancreatic cancers. The pathophysiology of peritoneal malignancy is complex and not fully understood. The two main hypotheses are the transformation of mesothelial cells (peritoneal primary tumour) and shedding of cells from a primary tumour with implantation of cells in the peritoneal cavity (peritoneal metastasis). Diagnosis is challenging and often requires modern imaging and interventional techniques, including surgical exploration. In the past decade, new treatments and multimodal strategies helped to improve patient survival and quality of life and the premise that peritoneal malignancies are fatal diseases has been dismissed as management strategies, including complete cytoreductive surgery embedded in perioperative systemic chemotherapy, can provide cure in selected patients. Furthermore, intraperitoneal chemotherapy has become an important part of combination treatments. Improving locoregional treatment delivery to enhance penetration to tumour nodules and reduce systemic uptake is one of the most active research areas. The current main challenges involve not only offering the best treatment option and developing intraperitoneal therapies that are equivalent to current systemic therapies but also defining the optimal treatment sequence according to primary tumour, disease extent and patient preferences. New imaging modalities, less invasive surgery, nanomedicines and targeted therapies are the basis for a new era of intraperitoneal therapy and are beginning to show encouraging outcomes.

show abstract

Characterizing the Patient Experience of CS/HIPEC Through In-Depth Interviews with Patients: Identification of Key Concepts in the Development of a Patient-Centered Program

Cited by 7 publications

References 12 publications

Guidelines for Perioperative Care in Cytoreductive Surgery (CRS) with or without hyperthermic IntraPEritoneal chemotherapy (HIPEC): Enhanced recovery after surgery (ERAS®) Society Recommendations — Part I: Preoperative and intraoperative management

Guidelines for Perioperative Care in Cytoreductive Surgery (CRS) with or without hyperthermic IntraPEritoneal chemotherapy (HIPEC): Enhanced recovery after surgery (ERAS®) Society Recommendations — Part I: Preoperative and intraoperative management

Systematic Review of Factors Affecting Quality of Life After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy

Primary and metastatic peritoneal surface malignancies

Contact Info

Product

Resources

About